Amberly buys WBC 105.71: Boehringer Ingelheimâs volasertib showed in a Phase II study an improvement in overall survival in older AML patients
The most common non-haematological adverse events for patients receiving the combination treatment were decreased white blood cells with fever and infections ... Pratt & Whitney, a unit of United Technologies Corp. (NYSE:UTX), and its supplier partners ... ...
30 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home